New Land (301277.SZ): Moxifloxacin Hydrochloride API Obtains CEP Certificate

Zhito Finance APP News, New Land (301277.SZ) announced that recently, the company received the Certificate of Suitability of the European Pharmacopoeia (hereinafter referred to as the "CEP Certificate") for moxifloxacin hydrochloride API issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM"). Moxifloxacin hydrochloride is a quinolone antibiotic used to treat infectious diseases caused by pathogens susceptible to this product, such as bacterial sinusitis, acute exacerbation of bacterial chronic bronchitis, community-acquired pneumonia, uncomplicated skin and skin structure infections, complicated intra-abdominal infections, complicated skin and skin structure infections, etc.